Fibonacci Retracements Explained: How to Spot Key Reversal Levels in 2026 A jump in 2026 earnings forecasts to 38% has brought institutional investors back into Russell 2000 stocks. Fed policy remains ...

While historical returns provide a useful starting point, they don’t tell the complete story. In this editorial, we discuss ...

The S&P/ASX Small Ordinaries Index (XSO) finished slightly weaker yesterday, slipping 5.30 points, or 0.15%, to 3,434.50.

Small-cap stocks posted a blistering performance in the first half of this year. The Russell 2000 Index surged 22% through June, marking its strongest first-half performance since ...

The Russell Microcap Index has more than doubled the performance of the S&P 500 this year . Microcap stocks as a group have soared this year. That comes with ...

Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so ...

Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...

Global merger activity reached a record $2.6 trillion in the first half of the year as companies pursued larger acquisitions, ...

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to ...

That is a big risk investors take when trying to find the winners and losers within the biotech sector. While we made the ...

The Russell 2000 has recently outperformed the S&P 500, and three factors are driving the move, according to Goldman Sachs. The small-cap stock index is up 20.5% since the start of the year and 37% ...

A caffeine giant, a growing CDMO business, and a recovering API segment. Can Aarti Pharmalabs convert a Rs 1,300+ crore capex ...